$RVMD

Horn Margaret A sold $15.0M of RVMD

Horn Margaret A (Chief Operating Officer) sold 93,575 shares of Revolution Medicines, Inc. (RVMD) at an average of $160.00 ($156.12–$160.17, $14.97M total) across 3 trades over 2025-06-16 to 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Horn Margaret A
Published Jun 17, 2026, 11:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 11:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RVMD
Neutral
medium confidence
Mentioned
$RVMD
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVMDNeutralLow
01

Why it matters

The disclosure provides a concrete, time-stamped insider selling event (~$14.97M) that can influence short-term sentiment, though 10b5-1 typically limits the signal of new negative information.

02

Market read

Traders may monitor for follow-on insider activity or correlate with upcoming company catalysts, but the filing alone is unlikely to drive a major repricing.

03

What to watch

The trades span multiple dates; the market may already have priced any earlier sale activity, leaving only the incremental effect of the latest filing.

Relevance 6/10Novelty 5/10Timing: Filed 2026-06-17 (after-hours/late day) for trades dated 2025-06-16 to 2026-06-17

Background

This is an SEC Form 4 insider transaction filing for Revolution Medicines, Inc., reporting officer (COO) share sales executed in open-market trades under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$RVMDNeutralMedium confidence
Context

Revolution Medicines COO Margaret A Horn sold ~$15.0M of RVMD shares in open-market transactions under a 10b5-1 plan, per SEC Form 4.

Expected impact

Likely limited immediate price impact; any reaction should be modest unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing discloses a large dollar-value sale by an officer, yet it is explicitly under a pre-arranged 10b5-1 plan, which typically dampens inference about new negative information.

Market effects

No direct sector read-through; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity/compensation mechanics rather than a change in fundamentals.

Key entities

  • Revolution Medicines, Inc.

    Subject of the Form 4 insider transaction; COO sold 93,575 shares for ~$14.97M under a 10b5-1 plan.

  • Horn Margaret A

    COO who executed the open-market sales; holdings after transaction reported as 154,647 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AZNMedAI 8/10

CHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launch

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

$RVMDMed

October 2026 EMA/CHMP recommendations

The European Medicines Agency's CHMP recommended six medicines, including Revolution Medicines' Rasonque, for approval. Rasonque targets metastatic pancreatic cancer and was prioritized under EMA's Cancer Medicines Pathfinder project.

$RVMDHigh

Guggenheim reiterates Buy on Revolution stock after EU regulatory opinion

Guggenheim maintained a Buy rating and $275 price target on Revolution Medicines (NASDAQ:RVMD) after the European Medicines Agency recommended approval of its drug Rasonque. The stock has risen 281% in the past year, though some analysts suggest it may be overvalued. Multiple firms have recently initiated coverage with positive ratings and price targets ranging from $226 to $318.

$LLYHigh

Lilly, Pfizer, J&J among winners of EU drug recommendations this month

The EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.

$RVMDHigh

William Blair initiates Revolution stock with outperform on RAS franchise

William Blair initiated coverage on Revolution Medicines (RVMD) with an Outperform rating and a $226 price target. The stock has gained 281% over the past year. The FDA approved Rasonque (daraxonrasib) for pancreatic cancer, with trials showing improved survival rates. Analysts cite strong early launch trends and commercial potential, though some note overvaluation. Multiple firms raised price targets following the approval.

$RVMDMed

Revolution Medicines receives EU committee backing for pancreatic cancer drug

Revolution Medicines (RVMD) announced the EMA's Committee for Medicinal Products for Human Use issued a positive opinion for RASONQUE as a monotherapy for adult patients with metastatic pancreatic adenocarcinoma. The recommendation is based on Phase 3 trial results showing RASONQUE improved overall survival (13.2 months vs. 6.7 months with chemotherapy) and progression-free survival (7.2 months vs. 3.6 months). The EMA's expedited review process was used.